Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
It is very uncertain whether SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE changes leaving the study early compared with MAINTENANCE RISPERIDONE/FGA (very low certainty).
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
It is very uncertain whether ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL changes leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia
It is very uncertain whether ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · patients with schizophrenia
It is very uncertain whether ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS changes leaving the study early due to adverse effects (overall tolerability… compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia
It is very uncertain whether BENZODIAZEPINES AS SOLE TREATMENT changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · patients with schizophrenia
1 finding from 1 review
Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia
It is very uncertain whether BENZODIAZEPINES changes leaving the study early due to any reason (overall acceptability of… compared with ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · patients with schizophrenia
It is very uncertain whether BENZODIAZEPINES changes leaving the study early due to adverse effects (overall tolerability… compared with ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Leaving the study early · schizophrenia
It is very uncertain whether technology‐mediated psychoeducation changes compliance/satisfaction: leaving the study early ‐ any reason compared with standard care intervention (very low certainty).
1 finding from 1 review
Intervention not reported
Leaving the study early ‐ Adverse event: Short‐term · schizophrenia
The intervention showed no clear difference in leaving the study early ‐ Adverse event: Short‐term; GRADE not reported.
1 finding from 1 review
Leaving the study early · patients with schizophrenia
Paliperidone palmitate leads to lower leaving the study early ‐ any reason Reported by trial author compared with placebo (high certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
Paliperidone palmitate showed no clear difference in leaving the study early ‐ any reason Reported by trial author compared with risperidone long‐acting injection (high certainty).
1 finding from 1 review
Leaving the study early ‐ lack of efficacy Reported by trial author · patients with schizophrenia
Paliperidone palmitate probably leads to higher leaving the study early ‐ lack of efficacy Reported by trial author compared with risperidone long‐acting injection (moderate certainty).
1 finding from 1 review
Leaving the study early · patients with psychosis‐induced aggression or agitation
It is very uncertain whether CHLORPROMAZINE changes leaving the study early compared with HALOPERIDOL (very low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with typical antipsychotics (low certainty).
1 finding from 1 review
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
It is very uncertain whether levomepromazine changes leaving the study early ‐ short term ‐ due to lack of efficacy compared with atypical antipsychotics (very low certainty).
1 finding from 1 review
Leaving the study early ‐ short term ‐ due to patient deterioration · patients with schizophrenia
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to patient deterioration compared with atypical antipsychotics (moderate certainty).
1 finding from 1 review
Leaving the study early ‐ short term ‐ lost to · patients with schizophrenia
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ lost to compared with atypical antipsychotics (low certainty).
1 finding from 1 review
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to lack of efficacy compared with typical antipsychotics (low certainty).
1 finding from 1 review